TrialNeurology2023

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.

Cecilia Monteiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.